IMNN Imunon (IMNN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0000749647
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
9
13F, latest reported quarter
What the filings say about IMNN
Insiders, 180 days
-$38.1K net sold
1 seller · 0% of sales under a 10b5-1 plan
Imunon insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Imunon, Inc. insiders sold a net $38.1K of stock across 9 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Aug 17, 2026.
- The trade is 87.2% of the 2,896 shares held after it.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and Corp Sec Eylward Susan sold about $3.9K of IMNN on Aug 31, 2026; 9 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Aug 3, 2026.
- The trade is 84.6% of the 2,896 shares held after it.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and Corp Sec Eylward Susan sold about $4.0K of IMNN on Aug 17, 2026; 9 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 20, 2026.
- The trade is 87.7% of the 2,896 shares held after it.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and Corp Sec Eylward Susan sold about $4.0K of IMNN on Aug 3, 2026; 9 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jul 6, 2026.
- The trade is 74.2% of the 2,896 shares held after it.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and Corp Sec Eylward Susan sold about $3.8K of IMNN on Jul 20, 2026; 9 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 29, 2026.
- The trade is 31.8% of the 2,896 shares held after it.
- No other insider sold within 30 days.
- 9 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel and Corp Sec Eylward Susan sold about $1.7K of IMNN on Jul 6, 2026; 9 funds added in the latest 13F quarter.9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$38.1K over 180 days
-$11.9K over 90 days
more than 58% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
9 funds bought in last quarter
below 86% of Pharma & Biotech
Revenue
+0.0% year over year
below 56% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
3.3% of the float short (float per yahoo 2026-10-26) · 1.2 days to cover · settled 2026-09-30
below 60% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch IMNN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-74.9%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IMNN: institutional holders (13F)
13F holdings, latest reported quarter
144,767 sh
$257.7K
34,364 sh
$247.8K
46,967 sh
$83.6K
31,629 sh
$56.3K
13,269 sh
$23.6K
Congress trades in IMNN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IMNN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
IMNN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$44.5K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$83.6K position · as of 2026-06-30
0.0%
Fidelity Series Total Market Index Fund
$10.3K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$3.9K position · as of 2026-05-31
0.0%
Fidelity Nasdaq Composite Index Fund
$355 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 3 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
0 active
3
Phase 3
1 active
3
Multi-phase
2 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $38.1K sold by insiders over 180 days, 9 funds added last quarter. Each figure is a federal filing, dated the day it went public.
IMNN financials
Revenue growth
0.0%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$500.0K
four quarters, 2022-01-01 to 2022-12-31
Revenue, TTM IMNN
| FY Jul 2026 | $500.0K |
| FY Dec 2025 | $500.0K |
| FY Dec 2024 | $500.0K |
| FY Dec 2023 | $500.0K |
| FY Dec 2022 | $500.0K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM IMNN
| FY Jul 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$15.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM IMNN
| FY Jul 2026 | -$15.4M |
| FY Dec 2025 | -$14.2M |
| FY Dec 2024 | -$18.9M |
| FY Dec 2023 | -$19.5M |
| FY Dec 2022 | -$23.4M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$3.7M |
| Sep 2025 | -$4.4M |
| Jun 2025 | -$3.0M |
| Mar 2025 | -$3.1M |
| Dec 2024 | -$4.4M |
| Sep 2024 | -$4.1M |
At each fiscal year end
Single quarter
Debt to equity
1.45x
long-term debt only, 2023-03-31 (39 months older than the period end); equity 2026-06-30
Debt to equity IMNN
| FY Jul 2026 | 1.45x |
| FY Dec 2025 | 0.86x |
| FY Dec 2024 | 1.43x |
| FY Dec 2023 | 0.45x |
| FY Dec 2022 | 0.20x |
| Jun 2026 | 1.45x |
| Mar 2026 | 1.81x |
| Dec 2025 | 0.86x |
| Sep 2025 | 1.49x |
| Jun 2025 | 2.29x |
| Mar 2025 | 13.45x |
| Dec 2024 | 1.43x |
| Sep 2024 | 0.74x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.48x
TTM operating cash flow over long-term debt only, 2023-03-31 (39 months older than the period end)
Cash flow to debt IMNN
| FY Jul 2026 | -2.48x |
| FY Dec 2025 | -2.29x |
| FY Dec 2024 | -3.10x |
| FY Dec 2023 | -3.13x |
| FY Dec 2022 | -3.87x |
| Jun 2026 | -2.48x |
| Mar 2026 | -2.47x |
| Dec 2025 | -2.29x |
| Sep 2025 | -2.41x |
| Jun 2025 | -2.35x |
| Mar 2025 | -2.60x |
| Dec 2024 | -3.10x |
| Sep 2024 | -2.99x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+416.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity IMNN
| FY Jul 2026 | +416.9% |
| FY Dec 2025 | +256.4% |
| FY Dec 2024 | -211.2% |
| FY Dec 2023 | -91.4% |
| FY Dec 2022 | -84.3% |
| Jun 2026 | +416.9% |
| Mar 2026 | +752.9% |
| Dec 2025 | +256.4% |
| Sep 2025 | -233.5% |
| Jun 2025 | -492.0% |
| Mar 2025 | -397.5% |
| Dec 2024 | -211.2% |
| Sep 2024 | -148.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+120.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets IMNN
| FY Jul 2026 | +120.1% |
| FY Dec 2025 | +131.7% |
| FY Dec 2024 | -117.7% |
| FY Dec 2023 | -59.2% |
| FY Dec 2022 | -60.8% |
| Jun 2026 | +120.1% |
| Mar 2026 | +192.8% |
| Dec 2025 | +131.7% |
| Sep 2025 | -122.6% |
| Jun 2025 | -170.4% |
| Mar 2025 | -168.0% |
| Dec 2024 | -117.7% |
| Sep 2024 | -99.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital IMNN
| FY Jul 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-216.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed IMNN
| FY Jul 2026 | -216.9% |
| FY Dec 2025 | -232.6% |
| FY Dec 2024 | -196.7% |
| FY Dec 2023 | -86.8% |
| FY Dec 2022 | -49.2% |
| Jun 2026 | -216.9% |
| Mar 2026 | -602.4% |
| Dec 2025 | -232.6% |
| Sep 2025 | -211.6% |
| Jun 2025 | -396.3% |
| Mar 2025 | -345.5% |
| Dec 2024 | -196.7% |
| Sep 2024 | -148.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing IMNN
| FY Jul 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.1M
market value at close 2026-10-26 on 2026-08-10 shares, plus long-term debt only, 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
Enterprise value IMNN
| FY Jul 2026 | $5.6M |
| FY Dec 2025 | $9.0M |
| FY Dec 2024 | $179.9M |
| FY Dec 2023 | $83.6M |
| FY Dec 2022 | $125.4M |
| Jun 2026 | $6.7M |
| Mar 2026 | $12.8M |
| Dec 2025 | $9.0M |
| Sep 2025 | $12.1M |
| Jun 2025 | $153.9M |
| Mar 2025 | $203.4M |
| Dec 2024 | $179.9M |
| Sep 2024 | $194.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-223.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield IMNN
| FY Jul 2026 | -239.4% |
| FY Dec 2025 | -121.2% |
| FY Dec 2024 | -10.5% |
| FY Dec 2023 | -23.4% |
| FY Dec 2022 | -17.8% |
| Jun 2026 | -205.7% |
| Mar 2026 | -132.8% |
| Dec 2025 | -121.2% |
| Sep 2025 | -132.9% |
| Jun 2025 | -9.5% |
| Mar 2025 | -8.0% |
| Dec 2024 | -10.5% |
| Sep 2024 | -9.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing IMNN
| FY Jul 2026 | n/a |
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | $500.0K |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M |
| Net income | $14.5M | -$18.6M | -$19.5M | -$35.9M |
| EPS (diluted) | -6.83 | -16.94 | -2.16 | -5.03 |
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M |
| Cash | $8.8M | $5.9M | $5.8M | $11.5M |
| Long-term debt | n/a | n/a | n/a | $6.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
IMNN Stock Sonar score 6/7 axes
Find similar shapesCompareIMNN ranks highest on risk and compliance (76th percentile) and profitability (69th), and lowest on institutional and government (14th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IMNN filings, in plain words
Are Imunon insiders buying or selling IMNN?
In the 180 days to 2026-10-28, Imunon insiders were net sellers, a net $38.1K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Imunon insiders were net sellers of IMNN, a net $38.1K across purchases and sales reported on Form 4 by 1 seller. None of the 6 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
